Preprogen’s focus is developing and advancing the first-and-only non-invasive at-home cell collection kit, PadKit™, for the early detection of endometrial cancer and other gynecologic cancers, known cancer markers (e.g., BRCA1, BRCA2), vaginal infections, infectious diseases including STDs, fetal conditions, and other women’s health issues.
Currently under development, PadKit is the first at-home gynecologic cancer cell collection screening kit designed to collect whole, intact endometrial cancer cells on a unique, comfortable, Interlabial Collection Pad™ (ICP).
Preprogen is empowering women’s health by pioneering an at-home endometrial cancer cell collection screening kit, with PadKit™. Prescribed by and under the comprehensive care of a physician, PadKit offers the first-and-only, non-invasive detection of endometrial cancer cells.
In addition to the early detection of abnormal cancer cells and other women’s health issues, Preprogen’s patented fetal cell science technology will potentially provide unique insights into the development of the fetus and its cells throughout pregnancy. The goal is to screen early for abnormal markers, including Trisomy 21 (i.e., Down’s Syndrome), fetal RH factor, Tay Sachs disease, Cystic Fibrosis, and standard screening for Fetal Fibronectin.